JPRN-UMIN000003156Completed未知
Randomized Phase II trial of TS-1 based thrapy vs TS-1 based therapy + LNT for advanced or Recurrent Gastric Cancer - TS-1 based thrapy vs TS-1 based therapy + LNT (Randomized Phase II trial)
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 90
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Drug hypersensitivity or severe drug allergy. 2) With infectious disease which needs treatment. 3) Uncontrolled medical conditions (e.g., congestive heart failure, ileus, interstitial pneumonia, pulmonary fibrosis, diabetes, interstitial pneumonia, pulmonary fibrosis, renal failure). 4) Patients with severe dysfunction of bone marrow 5) Patients with severe dysfunction of liver 6) Patients who need flucitosine 7) With uncontrolled pleural effusion or ascites. 8) Patients with any symptoms due to metastases to the central nervous system 9) Active concomitant malignancy. 10) Pregnant or lactating women 11) men with intent to bear baby 12) Any other patient whom the physician in charge of the study judges to be not eligible
Investigators
Similar Trials
Unknown
Phase 2
Randomized phase II trial of TS-1 monotherapy versus TS-1 plus gemcitabine therapy in patients with gemcitabine-resistant advanced pancreatic cancerPatients with unresectable advanced pancreatic cancer (Stage IV, TNM Classification) who were primarily resistant to gemcitabine monotherapyJPRN-UMIN000001103Keio University School of Medicine, Department of Medicine, Division of Gastroenterology80
Completed
Phase 2
A randomized phase II (/III) study of TXT/TS-1 (DS) combination vs CDDP/5-FU therapy (FUP) in metastatic gastric cancerChemotherapy-naïve metastatic gastric cancerJPRN-C000000104Hiroshima Cancer Therapy Development Organization (HiCTDO)130
Unknown
Phase 3
Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer.Advanced (nonresectable/recurrent) gastric cancerJPRN-jRCT1080220046Taiho Pharmaceutical Co., Ltd.
Completed
Phase 3
Randomized phase III study of TS-1 alone versus TS-1 plus Lentinan(LNT) in advanced or recurrent gastric cancer (AGC)Advanced or recurrent gastric cancer (AGC)JPRN-UMIN000000574Japanese Foundation for Multidisciplinary Treatment of Cancer300
Completed
Phase 2
Phase II Study of TS-1 with Patient-Reported Outcome(PRO) Evaluation in Elderly Patients with Advanced NSCLCon-small cell lung cancerJPRN-UMIN000002035Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School40